Article and Video CATEGORIES

Cancer Journey

Search By

Squamous Lung Cancer, Part 4: Immunotherapy by Dr. David Spigel
Author
Dr Spigel

Graphic showing cancer tumor cells and patient's T cellsDr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

 

[powerpress]

Squamous Lung Cancer, Part 4: Immunotherapy Audio Podcast

 

What you’ll hear in Part 4:

  • Immunotherapy treatment for squamous lung cancer

 

Glossary of some terms you’ll hear in Part 4:

Find more cancer definitions at the National Cancer Institute’s Dictionary of Cancer Terms

  • Adenocarcinoma – Cancer that begins in glandular (secretory) cells. Glandular cells are found in tissue that lines certain internal organs and makes and releases substances in the body, such as mucus, digestive juices, or other fluids. Most cancers of the breast, pancreas, lung, prostate, and colon are adenocarcinomas.
  • Antibody therapy – Treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells.
  • Immunotherapy – A type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
  • Receptor – A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific effect in the cell.
  • Squamous lung cancer – One of the three sub-types of lung cancer.

 

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on